We report a case of unusual annular erythema associated with myelodysplastic syndrome (MDS). A 58-year-old male with MDS developed annular erythema on his back, scaly erythema on the dorsa of hands, and exsudative erythema on his eyelids. Histological examination revealed a mononuclear cell infiltrate around vessels and follicles in the mid- to lower dermis. He had no history of treatment with granulocyte-colony-stimulating factor (G-CSF). Serum granulocyte-macrophage-colony-stimulating factor (GM-CSF) level was slightly elevated (5.84 pg/ml, normal <2.0 pg/ml), whereas other cytokines including G-CSF, IL-6, and IL-8 were within normal limits. Skin manifestations were much improved by systemic mepitiostane, and serum GM-CSF level returned to normal levels.

1.
Caughman W, Stern R, Haynes H: Neutrophilic dermatosis of myeloproliferative disorders: Atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 1983;9:751–758.
2.
Aractingi S, Bachmeyer C, Miclea J-M, Verola O, Rousselot P, Dubertret L, Daniel MT: Unusual specific cutaneous lesions in myelodysplastic syndromes. J Am Acad Dermatol 1995;33:187–191.
3.
Suzuki Y, Kuroda K, Kojima T, Fujita M, Iseki T, Shinkai H: Unusual cutaneous manifestations of myelodysplastic syndrome. Br J Dermatol 1995;133:483–486.
4.
Reuss-Borst MA, Pawelec G, Saal JG: Sweet’s syndrome associated with myelodysplasia: Possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993;84:356–358.
5.
Paydas S, Sahin B, Seyrek E: Sweet’s syndrome associated with G-CSF. Br J Haematol 1993;85:191–192.
6.
Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP: The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med 1992;116:996–998.
7.
Morioka N, Otsuka F, Nogita T, Igisu K, Urabe A, Ishibashi Y: Neutrophilic dermatosis with myelodysplastic syndrome: Nuclear segmentation anomalies of neutrophils in the skin lesion and in peripheral blood. J Am Acad Dermatol 1990;23:247–249.
8.
Fukutoku M, Shimizu S, Ogawa Y: Sweet’s syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol 1994;86:645–648.
9.
Prevost-Blank PL, Schwayder TA: Sweet’s syndrome secondary to granulocyte colony-stimulating factor. J Am Acad Dermatol 1996;35:995–997.
10.
Richard MA, Grob JJ, Laurans R, Hesse S, Brunet P, Stoppa AM, Bonerandi JJ, Berland Y, Maraninchi D: Sweet’s syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia. J Am Acad Dermatol 1996;35:629–631.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.